Core Facilities

Anticancer Biomolecule Screening Facility

Animal House


Hybridoma Lab

Zebrafish Lab

Lentiviral Particle Production Unit

Research Projects

Research Articles




BILGEN in vitro anticancer biomolecule screening service aims to identify novel biologically active molecules that can be considered as candidate anti-cancer drugs. Our service is operational since the beginning of 2007. Our facility served to many centers in Turkey (Hacettepe University, Ankara University, Ataturk University) and abroad (École nationale supérieure de chimie de Paris). So far we screened up to 700 synthetic or natural plant originated compounds for their potential cytotoxic anticancer activity. For this purpose we made 42000 experiments. In our initial screening procedure we use 3 human tumor cell lines (liver carcinoma Huh7, breast carcinoma T47-D and colon carcinoma HCT116). After the detection of an activity, further cell lines are tested. Dose response curve for each compound can be determined along with IC50 values. Our Screening methodology is based on NCI-SRB assay (Shoemaker, R. H. The NCI60 Human Tumour Cell line Anticancer Drug Screen. Nature Reviews, 6: 813-823, 2006.).

In addition our laboratory we developed an established in vitro kinase activity assay for the drug candidates. So far we identified 7 kinase inhibitors. Our preliminary results were presented International meetings (ILCA-2009, ISOPS-9, 42nd IUPAC Congress).

Experimental procedures
 Drug Screening